Clarivate PLC 10-Q quarterly reports

Clarivate Plc announced its second quarter 2026 financial results, reporting a net loss and detailing the agreement to divest its Life Sciences & Healthcare business for $600 million.

Clarivate Plc reported a slight revenue decrease in Q1 2026 compared to the prior year, but saw an improvement in operating income and Adjusted EBITDA margin.

Clarivate Plc reported a reduced net loss for Q3 2025, with revenues remaining flat for the quarter but declining for the nine-month period, as the company continues its Value Creation Plan and debt optimization efforts.

Clarivate Plc reported a narrower net loss for the second quarter and first half of 2025, driven by the absence of prior-year goodwill impairment, despite a decline in overall revenues and free cash flow as the company continues its Value Creation Plan and product group wind-downs.

Clarivate Plc's Q1 2025 results reveal a revenue decrease primarily due to divestitures and wind-downs, despite growth in recurring revenue and cost management efforts.

Clarivate's Q3 2024 results show a revenue decrease and a net loss, impacted by restructuring, impairments, and divestitures.

Clarivate PLC's second quarter 2024 results show a net loss, impacted by a significant goodwill impairment, despite some positive organic revenue growth in subscriptions.

Clarivate PLC's first quarter 2024 results show a slight revenue decrease and a net loss, impacted by restructuring and divestiture costs, while also highlighting ongoing strategic initiatives.